E-DRUG: Independent Drug and Healthcare Newsletter for January 2019
----------------------------------------------------------------------------------------
Newsletter, January 2019
Independent Drug & Healthcare Newsletter from the non-profit journal Prescrire International
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter :
Like what you see?
Subscribe to Prescrire International : Prescrire IN ENGLISH - Offers - Subscribe now, or renew subscription - <span style="font-size:13px">Subscribe or renew online</span>
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW Proton pump inhibitors: increased mortality
Proton pump inhibitors (PPIs) such as omeprazole are used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. PPIs have few severe adverse effects in the short term. But this is not the case in the long term.
Read more
--------------------------------------------------------------------------------
FREE DOWNLOAD In the January issue of Prescrire International: Pembrolizumab (Keytruda°) in urothelial carcinoma
In this month's sample review: Prescrire's editors rate pembrolizumab (Keytruda°) "Possibly helpful" in certain patients with locally advanced or metastatic urothelial carcinoma.
Read more
--------------------------------------------------------------------------------
SUBSCRIBE NOW Subscribe today for full access to top-quality content from Prescrire International
Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries).
Subscribe now
--------------------------------------------------------------------------------
Nonsteroidal anti-inflammatory drugs in pharyngitis: risk of peritonsillar abscess
To relieve fever or sore throat, it is better not to use nonsteroidal anti-inflammatory drugs (NSAIDs), but to use paracetamol instead.
Read more
--------------------------------------------------------------------------------
Drug companies enjoy impunity from EU authorities
Under European regulations, the European Commission can only impose a financial penalty on drug companies if their infringement has "substantial consequences for public health" and if they do not co-operate during the proceedings brought against them.
Read more
--------------------------------------------------------------------------------
COPD exacerbation: no systematic use of antibiotics
For episodes of moderate aggravation in patients with chronic obstructive pulmonary disease (COPD), it is preferable to prescribe antibiotics as a first-line treatment only when the suspicion of bacterial infection is reinforced by an increase in sputum purulence.
Read more
--------------------------------------------------------------------------------
ADVANCING HEALTHCARE POLICY "Implant Files" : Campaign for an effective marketing authorisation for high-risk medical devices (December 2018)
In a joint press release, several French associations, including Prescrire, join forces to condemn the health authorities' failure to adequately oversee the trade in high-risk medical devices.
Read more
--------------------------------------------------------------------------------
COMING SOON Enjoy these features, and more, in our upcoming issues
Dolutegravir and pregnancy: neural tube defects * Febrile seizure in children * Postpartum haemorrhage * Psychostimulant use by medical students in France * Non-occupational exposure to agricultural pesticides and Parkinson's disease...
Subscribe now
Prescrire International <international@prescrire.org>